Alpha Tau Medical (NASDAQ: DRTS) has hit a key milestone in its pancreatic cancer program, successfully treating the first pancreatic cancer patient in Europe with its…
April 21, 2026
BriaCell Highlights Potent Preclinical Anti‑Cancer Activity For Next‑Gen Bria‑OTS+ Platform
BriaCell Therapeutics (NASDAQ: BCTX) presented new preclinical data showing that its next‑generation Bria‑OTS+ off‑the‑shelf immunotherapy platform triggers strong, coordinated immune responses and robust tumor‑killing activity across…
Caris Life Sciences (NASDAQ: CAI) has introduced a multimodal, AI‑powered “immunotherapy treatment selection” signature for a subset of non‑small cell lung cancer (NSCLC) patients who are…
March 17, 2026
Candel Therapeutics Gains Momentum as Lead Cancer Therapy Advances Across Multiple Trials
Candel Therapeutics, Inc. (NASDAQ: CADL) continues to advance its lead oncology program following updated mid-stage clinical data for its investigational therapy CAN-2409 (aglatimagene besadenovec). The…
February 24, 2026
Cancer Immunotherapy Breakthroughs Are Transforming Oncology and Driving Biotech Growth
Cancer immunotherapy has become one of the most important breakthroughs in modern medicine, reshaping how cancer is treated and creating significant commercial opportunities for leading…
January 07, 2026
BBOT’s ON/OFF Biology: A Game-Changer in Oncology
BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) unveiled promising updates across its oncology pipeline, solidifying its position as a leader in innovative cancer therapies. The standout…
Cencora (NYSE: COR) is moving forward with plans to acquire majority control of OneOncology, a U.S.-based oncology care network, in a transaction that values the…
December 10, 2025
MAIA Targets Large Immunotherapy Opportunity with Novel Telomere-Focused Cancer Approach
MAIA Biotechnology (NYSE American: MAIA) outlined its strategy to address a significant unmet need in oncology through its lead asset, atevagenosine (THIO), a differentiated cancer…